Gramine Derivatives Targeting Ca2+ Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases

Journal of Medicinal Chemistry

Volumn 59, Issue 13, 2016, Pages 6265-6280

  Lajarín Cuesta, Rocío ^a   Nanclares, Carmen ^a   Arranz Tagarro, Juan Alberto ^a   González Lafuente, Laura ^c   Arribas, Raquel L ^a   Araujo De Brito, Monique ^b   Gandía, Luis ^a   De Los Ríos, Cristóbal ^a,c  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 BENZYL 5 BROMO 1H INDOL 3 YL) N,N DIMETHYLMETHANAMINE; 1 (1 BENZYL 5 METHYL 1H INDOL 3 YL) N,N DIMETHYLMETHANAMINE; 1 (4 CHLOROBUTYL) 5 METHYL 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 1 (5 BROMO 1 BUTYL 1H INDOL 3 YL) N,N DIMETHYLMETHANAMINE; 1 (5 BROMO 1H INDOL 3 YL) N,N DIMETHYLMETHANAMINE; 1 BENZYL 5 BROMO 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 1 BENZYL 5 METHYL 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 1 BUTYL 5 METHYL 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 1 [5 BROMO 1 (PROP 2 YN 1 YL) 1H INDOL 3 YL] N,N DIMETHYLMETHANAMINE; 1 [5 BROMO 1 [4 (PIPERIDIN 1 YL)BUTYL] 1H INDOL 3 YL] N,N DIMETHYLMETHANAMINE; 3 (DIMETHYLAMINOMETHYL) 1H INDOLE DERIVATIVE; 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 4 [5 BROMO 3 (PIPERIDIN 1 YLMETHYL) 1H INDOL 1 YL]BUTANOATE; 4 [5 BROMO 3 [(DIMETHYLAMINO)METHYL] 1H INDOL 1 YL]BUTANOATE; 5 BROMO 1 (4 CHLOROBUTYL) 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 5 BROMO 1 BUTYL 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 5 BROMO 1 [4 (PIPERIDIN 1 YL)BUTYL] 1H INDOLE; 5 BROMO 3 (PIPERIDIN 1 YLMETHYL) 1 (PROP 2 YN 1 YL) 1H INDOLE; 5 BROMO 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; 5 METHYL 1 [4 (PIPERIDIN 1 YL)BUTYL] 1H INDOLE; 5 METHYL 3 (PIPERIDIN 1 YLMETHYL) 1 (PROP 2 YN 1 YL) 1H INDOLE; 5 METHYL 3 (PIPERIDIN 1 YLMETHYL) 1H INDOLE; GRAMINE; N,N DIMETHYL 1 [5 METHYL 1 (PROP 2 YN 1 YL) 1H INDOL 3 YL]METHANAMINE; NEUROPROTECTIVE AGENT; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ALKALOID; CALCIUM CHANNEL; PHOSPHOPROTEIN PHOSPHATASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATCH CLAMP TECHNIQUE; PROTEIN DEPHOSPHORYLATION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; NEURODEGENERATIVE DISEASES; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ALKALOIDS; ANIMALS; CALCIUM CHANNELS; CATTLE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HUMANS; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PHOSPHOPROTEIN PHOSPHATASES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84978705085     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00478     Document Type: Article

References (95)

1. Alzheimer, A. Über einen eigenartige erkrankung der hirnrinde Allg. Z. Psych. 1907, 64, 146-148
2. Scheltens, P.; Blennow, K.; Breteler, M. M.; de Strooper, B.; Frisoni, G. B.; Salloway, S.; Van der Flier, W. M. Alzheimer's disease Lancet 2016, 10.1016/S0140-6736(15)01124-1
3. Anand, R.; Gill, K. D.; Mahdi, A. A. Therapeutics of Alzheimer's disease: Past, present and future Neuropharmacology 2014, 76 (Part A) 27-50 10.1016/j.neuropharm.2013.07.004
4. Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials Nat. Rev. Drug Discovery 2012, 11, 657-660 10.1038/nrd3842
5. Herrup, K. The case for rejecting the amyloid cascade hypothesis Nat. Neurosci. 2015, 18, 794-799 10.1038/nn.4017
6. Iqbal, K.; Liu, F.; Gong, C. X. Tau and neurodegenerative disease: the story so far Nat. Rev. Neurol. 2016, 12, 15-27 10.1038/nrneurol.2015.225
7. Salahuddin, P.; Fatima, M. T.; Abdelhameed, A. S.; Nusrat, S.; Khan, R. H. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches Eur. J. Med. Chem. 2016, 114, 41-58 10.1016/j.ejmech.2016.02.065
8. Bulic, B.; Pickhardt, M.; Mandelkow, E. M.; Mandelkow, E. Tau protein and tau aggregation inhibitors Neuropharmacology 2010, 59, 276-289 10.1016/j.neuropharm.2010.01.016
9. Gong, C. X.; Iqbal, K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease Curr. Med. Chem. 2008, 15, 2321-2328 10.2174/092986708785909111
10. Carreiras, M. C.; Mendes, E.; Perry, M. J.; Francisco, A. P.; Marco-Contelles, J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics Curr. Top. Med. Chem. 2013, 13, 1745-1770 10.2174/15680266113139990135
11. Guzior, N.; Wieckowska, A.; Panek, D.; Malawska, B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease Curr. Med. Chem. 2015, 22, 373-404 10.2174/0929867321666141106122628
12. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Lupp, A.; Peng, S.; Fleck, C.; Zhang, Y.; Lehmann, J. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity J. Med. Chem. 2008, 51, 7666-7669 10.1021/jm801131a
13. Simoni, E.; Serafini, M. M.; Bartolini, M.; Caporaso, R.; Pinto, A.; Necchi, D.; Fiori, J.; Andrisano, V.; Minarini, A.; Lanni, C.; Rosini, M. Nature-inspired multifunctional ligands: focusing on amyloid-based molecular mechanisms of Alzheimer's disease ChemMedChem 2015, 10.1002/cmdc.201500422
14. Di Martino, R. M.; De Simone, A.; Andrisano, V.; Bisignano, P.; Bisi, A.; Gobbi, S.; Rampa, A.; Fato, R.; Bergamini, C.; Perez, D. I.; Martinez, A.; Bottegoni, G.; Cavalli, A.; Belluti, F. Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3beta inhibitors J. Med. Chem. 2016, 59, 531-544 10.1021/acs.jmedchem.5b00894
15. Bolea, I.; Juarez-Jimenez, J.; de Los Rios, C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 2011, 54, 8251-8270 10.1021/jm200853t
16. Romero, A.; Egea, J.; Gonzalez-Munoz, G. C.; Martin de Saavedra, M. D.; del Barrio, L.; Rodriguez-Franco, M. I.; Conde, S.; Lopez, M. G.; Villarroya, M.; de los Rios, C. ITH12410/SC058: a new neuroprotective compound with potential in the treatment of Alzheimer's disease ACS Chem. Neurosci. 2014, 5, 770-775 10.1021/cn500131t
17. Martinez-Sanz, F. J.; Lajarin-Cuesta, R.; Moreno-Ortega, A. J.; Gonzalez-Lafuente, L.; Fernandez-Morales, J. C.; Lopez-Arribas, R.; Cano-Abad, M. F.; de los Rios, C. Benzothiazepine CGP37157 analogues exert cytoprotection in various in vitro models of neurodegeneration ACS Chem. Neurosci. 2015, 6, 1626-1636 10.1021/acschemneuro.5b00161
18. Egea, J.; de los Rios, C. 1,8-Naphthyridine derivatives as cholinesterases inhibitors and cell Ca2+ regulators, a multitarget strategy for Alzheimer's disease Curr. Top. Med. Chem. 2011, 11, 2807-2823 10.2174/156802611798184418
19. Samadi, A.; Valderas, C.; de los Ríos, C.; Bastida, A.; Chioua, M.; González-Lafuente, L.; Colmena, I.; Gandía, L.; Romero, A.; del Barrio, L.; Martín-de-Saavedra, M. D.; López, M. G.; Villarroya, M.; Marco-Contelles, J. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles Bioorg. Med. Chem. 2011, 19, 122-133 10.1016/j.bmc.2010.11.040
20. Zundorf, G.; Reiser, G. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection Antioxid. Redox Signaling 2011, 14, 1275-1288 10.1089/ars.2010.3359
21. Riascos, D.; Nicholas, A.; Samaeekia, R.; Yukhananov, R.; Mesulam, M. M.; Bigio, E. H.; Weintraub, S.; Guo, L.; Geula, C. Alterations of Ca(2)(+)-responsive proteins within cholinergic neurons in aging and Alzheimer's disease Neurobiol. Aging 2014, 35, 1325-1333 10.1016/j.neurobiolaging.2013.12.017
22. Resende, R.; Pereira, C.; Agostinho, P.; Vieira, A. P.; Malva, J. O.; Oliveira, C. R. Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis Brain Res. 2007, 1143, 11-21 10.1016/j.brainres.2007.01.071
23. Mark, R. J.; Hensley, K.; Butterfield, D. A.; Mattson, M. P. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death J. Neurosci. 1995, 15, 6239-6249
24. Fernandez-Morales, J. C.; Arranz-Tagarro, J. A.; Calvo-Gallardo, E.; Maroto, M.; Padin, J. F.; Garcia, A. G. Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease ACS Chem. Neurosci. 2012, 3, 873-883 10.1021/cn3001069
25. Nimmrich, V.; Eckert, A. Calcium channel blockers and dementia Br. J. Pharmacol. 2013, 169, 1203-1210 10.1111/bph.12240
26. Zamponi, G. W. Targeting voltage-gated calcium channels in neurological and psychiatric diseases Nat. Rev. Drug Discovery 2016, 15, 19-34 10.1038/nrd.2015.5
27. Asakura, K.; Matsuo, Y.; Kanemasa, T.; Ninomiya, M. P/Q-type Ca2+ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats Brain Res. 1997, 776, 140-145 10.1016/S0006-8993(97)00975-X
28. Berman, R. F.; Verweij, B. H.; Muizelaar, J. P. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats J. Neurosurg. 2000, 93, 821-828 10.3171/jns.2000.93.5.0821
29. Hosaka, T.; Yamamoto, Y. L.; Diksic, M. Efficacy of retrograde perfusion of the cerebral vein with verapamil after focal ischemia in rat brain Stroke 1991, 22, 1562-1566 10.1161/01.STR.22.12.1562
30. Paris, D.; Bachmeier, C.; Patel, N.; Quadros, A.; Volmar, C. H.; Laporte, V.; Ganey, J.; Beaulieu-Abdelahad, D.; Ait-Ghezala, G.; Crawford, F.; Mullan, M. J. Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier Mol. Med. 2011, 17, 149-162 10.2119/molmed.2010.00180
31. Lopez-Arrieta, J. M.; Birks, J. Nimodipine for primary degenerative, mixed and vascular dementia Cochrane Database Syst. Rev. 2002, CD000147 10.1002/14651858.CD000147
32. Lajarin-Cuesta, R.; Arribas, R. L.; De Los Rios, C. Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015) Expert Opin. Ther. Pat. 2016, 26, 389-407 10.1517/13543776.2016.1135903
33. Tell, V.; Hilgeroth, A. Recent developments of protein kinase inhibitors as potential AD therapeutics Front. Cell. Neurosci. 2013, 7, 189 10.3389/fncel.2013.00189
34. Lovestone, S.; Boada, M.; Dubois, B.; Hull, M.; Rinne, J. O.; Huppertz, H. J.; Calero, M.; Andrés, M. V.; Gómez-Carrillo, B.; Leon, T.; del Ser, T. A phase II trial of tideglusib in Alzheimer's disease J. Alzheimer's Dis. 2015, 45, 75-88 10.3233/JAD-141959
35. Zhang, M.; Yogesha, S. D.; Mayfield, J. E.; Gill, G. N.; Zhang, Y. Viewing serine/threonine protein phosphatases through the eyes of drug designers FEBS J. 2013, 280, 4739-4760 10.1111/febs.12481
36. Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C. X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation Eur. J. Neurosci. 2005, 22, 1942-1950 10.1111/j.1460-9568.2005.04391.x
37. Gong, C. X.; Liu, F.; Wu, G.; Rossie, S.; Wegiel, J.; Li, L.; Grundke-Iqbal, I.; Iqbal, K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5 J. Neurochem. 2004, 88, 298-310 10.1111/j.1471-4159.2004.02147.x
38. Vogelsberg-Ragaglia, V.; Schuck, T.; Trojanowski, J. Q.; Lee, V. M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus Exp. Neurol. 2001, 168, 402-412 10.1006/exnr.2001.7630
39. Sontag, E.; Luangpirom, A.; Hladik, C.; Mudrak, I.; Ogris, E.; Speciale, S.; White, C. L., 3rd. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology J. Neuropathol. Exp. Neurol. 2004, 63, 287-301 10.1093/jnen/63.4.287
40. Tanimukai, H.; Grundke-Iqbal, I.; Iqbal, K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease Am. J. Pathol. 2005, 166, 1761-1771 10.1016/S0002-9440(10)62486-8
41. Chen, S.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A J. Biol. Chem. 2008, 283, 10513-10521 10.1074/jbc.M709852200
42. Longin, S.; Zwaenepoel, K.; Louis, J. V.; Dilworth, S.; Goris, J.; Janssens, V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit J. Biol. Chem. 2007, 282, 26971-26980 10.1074/jbc.M704059200
43. Sontag, E.; Hladik, C.; Montgomery, L.; Luangpirom, A.; Mudrak, I.; Ogris, E.; White, C. L., 3rd. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis J. Neuropathol. Exp. Neurol. 2004, 63, 1080-1091 10.1093/jnen/63.10.1080
44. Drewes, G.; Mandelkow, E. M.; Baumann, K.; Goris, J.; Merlevede, W.; Mandelkow, E. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A FEBS Lett. 1993, 336, 425-432 10.1016/0014-5793(93)80850-T
45. Sontag, E.; Nunbhakdi-Craig, V.; Lee, G.; Brandt, R.; Kamibayashi, C.; Kuret, J.; White, C. L., III; Mumby, M. C.; Bloom, G. S. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies J. Biol. Chem. 1999, 274, 25490-25498 10.1074/jbc.274.36.25490
46. Gong, C. X.; Grundke-Iqbal, I.; Iqbal, K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A Neuroscience 1994, 61, 765-772 10.1016/0306-4522(94)90400-6
47. Ma, O. K.; Sucher, N. J. Molecular interaction of NMDA receptor subunit NR3A with protein phosphatase 2A NeuroReport 2004, 15, 1447-1450 10.1097/01.wnr.0000132773.41720.2d
48. Zhu, M.; Wang, J.; Liu, M.; Du, D.; Xia, C.; Shen, L.; Zhu, D. Upregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats PLoS One 2012, 7, e51552 10.1371/journal.pone.0051552
49. Martin, L.; Latypova, X.; Wilson, C. M.; Magnaudeix, A.; Perrin, M. L.; Yardin, C.; Terro, F. Tau protein kinases: involvement in Alzheimer's disease Ageing Res. Rev. 2013, 12, 289-309 10.1016/j.arr.2012.06.003
50. de Los Rios, C.; Egea, J.; Marco-Contelles, J.; Leon, R.; Samadi, A.; Iriepa, I.; Moraleda, I.; Galvez, E.; Garcia, A. G.; Lopez, M. G.; Villarroya, M.; Romero, A. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives J. Med. Chem. 2010, 53, 5129-5143 10.1021/jm901902w
51. Lorrio, S.; Romero, A.; Gonzalez-Lafuente, L.; Lajarin-Cuesta, R.; Martinez-Sanz, F. J.; Estrada, M.; Samadi, A.; Marco-Contelles, J.; Rodriguez-Franco, M. I.; Villarroya, M.; Lopez, M. G.; de los Rios, C. PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice ACS Chem. Neurosci. 2013, 4, 1267-1277 10.1021/cn400050p
52. Settimo, A. D.; Primofiore, G.; Ferrarini, P. L. Bromoderivatives of gramines. Preparation and pharmacological properties Eur. J. Med. Chem. 1983, 18, 261-267
53. Iwata, S.; Saito, S.; Kon-ya, K.; Shizuri, Y.; Ohizumi, Y. Novel marine-derived halogen-containing gramine analogues induce vasorelaxation in isolated rat aorta Eur. J. Pharmacol. 2001, 432, 63-70 10.1016/S0014-2999(01)01476-5
54. Pelech, S.; Cohen, P. The protein phosphatases involved in cellular regulation. 1. Modulation of protein phosphatases-1 and 2A by histone H1, protamine, polylysine and heparin Eur. J. Biochem. 1985, 148, 245-251 10.1111/j.1432-1033.1985.tb08832.x
55. Voronkov, M.; Braithwaite, S. P.; Stock, J. B. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease Future Med. Chem. 2011, 3, 821-833 10.4155/fmc.11.47
56. Lambrecht, C.; Haesen, D.; Sents, W.; Ivanova, E.; Janssens, V. Structure, regulation, and pharmacological modulation of PP2A phosphatases Methods Mol. Biol. 2013, 1053, 283-305 10.1007/978-1-62703-562-0-17
57. Gurer-Orhan, H.; Suzen, S. Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds: antioxidant, prooxidant and inhibitor of bioactivation reactions Curr. Med. Chem. 2015, 22, 490-499 10.2174/0929867321666141215095259
58. Aiello, F.; Valacchi, G. Synthesis and evaluation of indole based molecules for treatment of oxidative stress related diseases Curr. Top. Med. Chem. 2014, 14, 2576-2589 10.2174/1568026614666141203142926
59. Camacho, M. E.; Carrion, M. D.; Lopez-Cara, L. C.; Entrena, A.; Gallo, M. A.; Espinosa, A.; Escames, G.; Acuna-Castroviejo, D. Melatonin synthetic analogs as nitric oxide synthase inhibitors Mini-Rev. Med. Chem. 2012, 12, 600-617 10.2174/138955712800626674
60. Semenov, B. B.; Granik, V. G. Chemistry of N-(1H-indol-3-ylmethyl)-N,N-dimethylamine (Gramine): A Review Pharm. Chem. J. 2004, 38, 287-310 10.1023/B:PHAC.0000048140.06266.63
61. Palmieri, A.; Petrini, M.; Shaikh, R. R. Synthesis of 3-substituted indoles via reactive alkylideneindolenine intermediates Org. Biomol. Chem. 2010, 8, 1259-1270 10.1039/B919891A
62. Ilic, N.; Habus, I.; Barkawi, L. S.; Park, S.; Stefanic, Z.; Kojic-Prodic, B.; Cohen, J. D.; Magnus, V. Aminoethyl-substituted indole-3-acetic acids for the preparation of tagged and carrier-linked auxin Bioorg. Med. Chem. 2005, 13, 3229-3240 10.1016/j.bmc.2005.02.046
63. Gonzalez-Lafuente, L.; Egea, J.; Leon, R.; Martinez-Sanz, F. J.; Monjas, L.; Perez, C.; Merino, C.; Garcia-De Diego, A. M.; Rodriguez-Franco, M. I.; Garcia, A. G.; Villarroya, M.; Lopez, M. G.; de Los Rios, C. Benzothiazepine CGP37157 and its isosteric 2′-methyl analogue provide neuroprotection and block cell calcium entry ACS Chem. Neurosci. 2012, 3, 519-529 10.1021/cn300009e
64. Sousa, S. R.; Vetter, I.; Ragnarsson, L.; Lewis, R. J. Expression and pharmacology of endogenous Cav channels in SH-SY5Y human neuroblastoma cells PLoS One 2013, 8, e59293 10.1371/journal.pone.0059293
65. Vaughan, P. F.; Peers, C.; Walker, J. H. The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release Gen. Pharmacol. 1995, 26, 1191-1201 10.1016/0306-3623(94)00312-B
66. Reeve, H. L.; Vaughan, P. F.; Peers, C. Calcium channel currents in undifferentiated human neuroblastoma (SH-SY5Y) cells: actions and possible interactions of dihydropyridines and omega-conotoxin Eur. J. Neurosci. 1994, 6, 943-952 10.1111/j.1460-9568.1994.tb00588.x
67. Albillos, A.; Garcia, A. G.; Olivera, B.; Gandia, L. Re-evaluation of the P/Q Ca2+ channel components of Ba2+ currents in bovine chromaffin cells superfused with solutions containing low and high Ba2+ concentrations Pfluegers Arch. 1996, 432, 1030-1038 10.1007/s004240050231
68. Arranz-Tagarro, J. A.; de los Rios, C.; Garcia, A. G.; Padin, J. F. Recent patents on calcium channel blockers: emphasis on CNS diseases Expert Opin. Ther. Pat. 2014, 24, 959-977 10.1517/13543776.2014.940892
69. Hillyard, D. R.; Monje, V. D.; Mintz, I. M.; Bean, B. P.; Nadasdi, L.; Ramachandran, J.; Miljanich, G.; Azimi-Zoonooz, A.; McIntosh, J. M.; Cruz, L. J.; Imperial, J. S.; Olivera, B. M. A new Conus peptide ligand for mammalian presynaptic Ca2+ channels Neuron 1992, 9, 69-77 10.1016/0896-6273(92)90221-X
70. Xing, Y.; Xu, Y.; Chen, Y.; Jeffrey, P. D.; Chao, Y.; Lin, Z.; Li, Z.; Strack, S.; Stock, J. B.; Shi, Y. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins Cell 2006, 127, 341-353 10.1016/j.cell.2006.09.025
71. Sun, L.; Liu, S. Y.; Zhou, X. W.; Wang, X. C.; Liu, R.; Wang, Q.; Wang, J. Z. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats Neuroscience 2003, 118, 1175-1182 10.1016/S0306-4522(02)00697-8
72. Perez, M.; Hernandez, F.; Gomez-Ramos, A.; Smith, M.; Perry, G.; Avila, J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells Eur. J. Biochem. 2002, 269, 1484-1489 10.1046/j.1432-1033.2002.02794.x
73. Swingle, M.; Ni, L.; Honkanen, R. E. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse Methods Mol. Biol. 2007, 365, 23-38 10.1385/1-59745-267-X:23
74. McAvoy, T.; Nairn, A. C. Serine/threonine protein phosphatase assays. In Current Protocols in Molecular Biology; Ausubel, F. M.; Brent, R.; Kingston, R. E.; Moore, D. D.; Seidman, J. G.; Smith, J. A.; Struhl, K., Eds. John Wiley & Sons: New York, 2010; Chapter 18, Unit 18.18, 10.1002/0471142727.mb1818s92
75. Denu, J. M.; Lohse, D. L.; Vijayalakshmi, J.; Saper, M. A.; Dixon, J. E. Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 2493-2498 10.1073/pnas.93.6.2493
76. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277 10.1016/0022-1759(86)90368-6
77. Nicolau, S. M.; de Diego, A. M.; Cortes, L.; Egea, J.; Gonzalez, J. C.; Mosquera, M.; Lopez, M. G.; Hernandez-Guijo, J. M.; Garcia, A. G. Mitochondrial Na+/Ca2+-exchanger blocker CGP37157 protects against chromaffin cell death elicited by veratridine J. Pharmacol. Exp. Ther. 2009, 330, 844-854 10.1124/jpet.109.154765
78. Kolok, S.; Nagy, J.; Szombathelyi, Z.; Tarnawa, I. Functional characterization of sodium channel blockers by membrane potential measurements in cerebellar neurons: prediction of compound preference for the open/inactivated state Neurochem. Int. 2006, 49, 593-604 10.1016/j.neuint.2006.04.014
79. Koh, P. O. Melatonin attenuates decrease of protein phosphatase 2A subunit B in ischemic brain injury J. Pineal Res. 2012, 52, 57-61 10.1111/j.1600-079X.2011.00918.x
80. Martinez-Sanz, F. J.; Lajarin-Cuesta, R.; Gonzalez-Lafuente, L.; Moreno-Ortega, A. J.; Punzon, E.; Cano-Abad, M. F.; de Los Rios, C. Neuroprotective profile of pyridothiazepines with blocking activity of the mitochondrial Na(+)/Ca(2+) exchanger Eur. J. Med. Chem. 2016, 109, 114-123 10.1016/j.ejmech.2015.12.043
81. Lewerenz, J.; Maher, P. Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence? Front. Neurosci. 2015, 9, 469 10.3389/fnins.2015.00469
82. Chan, S. F.; Sucher, N. J. An NMDA receptor signaling complex with protein phosphatase 2A J. Neurosci. 2001, 21, 7985-7992
83. Zimmer, E. R.; Leuzy, A.; Souza, D. O.; Portela, L. V. Inhibition of protein phosphatase 2A: focus on the glutamatergic system Mol. Neurobiol. 2015, 10.1007/s12035-015-9321-0
84. Triggle, D. J. Drug targets in the voltage-gated calcium channel family: why some are and some are not Assay Drug Dev. Technol. 2003, 1, 719-733 10.1089/154065803770381075
85. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740 10.1021/jm901137j
86. Na, Y. M.; Le Borgne, M.; Pagniez, F.; Le Baut, G.; Le Pape, P. Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives Eur. J. Med. Chem. 2003, 38, 75-87 10.1016/S0223-5234(02)00005-3
87. Evans, D. A.; Scheidt, K. A.; Fandrick, K. R.; Lam, H. W.; Wu, J. Enantioselective indole Friedel - Crafts alkylations catalyzed by bis(oxazolinyl)pyridine-scandium(III) triflate complexes J. Am. Chem. Soc. 2003, 125, 10780-10781 10.1021/ja036985c
88. Evans, D. A.; Fandrick, K. R.; Song, H. J. Enantioselective Friedel-Crafts alkylations of alpha,beta-unsaturated 2-acyl imidazoles catalyzed by bis(oxazolinyl)pyridine-scandium(III) triflate complexes J. Am. Chem. Soc. 2005, 127, 8942-8943 10.1021/ja052433d
89. Haider, N.; Kabicher, T.; Kaferbock, J.; Plenk, A. Synthesis and in-vitro antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds Molecules 2007, 12, 1900-1909 10.3390/12081900
90. Martelli, C.; Coronnello, M.; Dei, S.; Manetti, D.; Orlandi, F.; Scapecchi, S.; Novella Romanelli, M.; Salerno, M.; Mini, E.; Teodori, E. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors J. Med. Chem. 2010, 53, 1755-1762 10.1021/jm9016174
91. Henry, D. W.; Leete, E. Amine oxides. I. Gramine oxide J. Am. Chem. Soc. 1957, 79, 5254-5256 10.1021/ja01576a051
92. Miranda, S.; Lopez-Alvarado, P.; Avendano, C.; Menendez, J. C. Convenient synthesis of highly functionalized, 3,4-disubstituted indole building blocks Open Org. Chem. J. 2007, 1, 1-12 10.2174/1874095200701010001
93. Thomsen, R.; Christensen, M. H. MolDock: a new technique for high-accuracy molecular docking J. Med. Chem. 2006, 49, 3315-3321 10.1021/jm051197e
94. Moro, M. A.; Lopez, M. G.; Gandia, L.; Michelena, P.; Garcia, A. G. Separation and culture of living adrenaline- and noradrenaline-containing cells from bovine adrenal medullae Anal. Biochem. 1990, 185, 243-248 10.1016/0003-2697(90)90287-J
95. Hamill, O. P.; Marty, A.; Neher, E.; Sakmann, B.; Sigworth, F. J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches Pfluegers Arch. 1981, 391, 85-100 10.1007/BF00656997